Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors

Inclusion Criteria

• Part 1: Breast Cancer (BC)

• Refractory Hormone Receptor Positive (HR+), Human Epidermal Growth FactorReceptor 2 Negative (HER2-) BC

• Part 1A/Part 1D/Part1E also include: Refractory HR-positive/HER2-positive BC

• Part 1: Tumors other than BC (Part 1A/Part 1D/Part 1E): NSCLC, prostate, CRC,liposarcoma, or tumors with previously confirmed CDK4 or CCND1 amplificationaccording to local standard tests

• Part 1F: prostate cancer

• Part 2A, 2B, 2C and 2E:

• HR-positive/HER2-negative BC

• Patients who are either postmenopausal women or pre/peri-menopausal (Part 2Conly)

• Part 1D: metastatic castration resistant prostate cancer

• Lesion:

• Part 1: evaluable lesion (including skin or bone lesion only)

• Part 2A, 2B, 2C and 2E: measurable lesion per RECIST v1.1

• Part 2D: Participants with evaluable disease as per PCWG3; participants withbone metastases only are allowed. Participants with biochemical recurrence onlyare excluded.

• Prior systemic Treatment

• Part 1: HR-positive/HER2-negative BC

• At least 1 line of SOC, including CD4/6 inhibitor therapy for advanced ormetastatic disease, or if CDK4/6 inhibitors are not considered appropriatein the opinion of the investigator

• At least 1 line of anti-endocrine in countries without CDK4/6 inhibitorapproval or reimbursement, for advanced or metastatic disease

• HR-positive/HER2-positive BC (Parts 1A/1D/1E): at least 1 prior treatmentof approved HER2 targeting therapy

• Tumors other than BC (Parts 1A/1D/1E/1F): tumor that is resistant to atleast 2 lines of SOC for advanced or recurrent disease or for which nostandard therapy is available

• Part 2A and 2E: participants must have received at least 1 line of standard ofcare (including prior CDK4/6i) for advanced/metastatic disease; Prior chemo isallowed; Prior fulvestrant, mTOR and/or PI3K inhibitors are allowed

• Part 2B: participants who have not received any prior systemic anti-cancertherapies for advanced/metastatic BC

• Part 2C:

• Progressed during treatment or within 12 months of completion of adjuvanttherapy with an aromatase inhibitor if postmenopausal, or tamoxifen if preor perimenopausal, or

• Progressed while on or within 1 month after the endo the prior aromataseinhibitor therapy for advanced/metastatic BC if postmenopausal or priorendocrine treatment for advanced/metastatic BC if pre or perimenopausal

• One previous line of chemotherapy for advanced/metastatic disease isallowed in addition to endocrine therapy

• Part 2D:

• Received prior abiraterone; enzalutamide and CDK4i naive

• 0-1 line of chemotherapy is allowed General Inclusion Criteria

• All participants must be refractory to or intolerant of existing therapies known toprovide clinical benefit for their condition.

• Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1

• Adequate renal, liver, and bone marrow function

Exclusion Criteria:

• Part 1D: participants who have had a gastrectomy or have dietary or otherrestrictions that preclude a 10 hour overnight fast or consumption of the high fat,high calorie meal

• Part 2B: prior neoadjuvant or adjuvant treatment with a non-steroidal aromataseinhibitor with disease recurrence while on or within 12 months of completingtreatment. Prior treatment with any CDK4/6 inhibitor

• Part 2C: prior treatment with any CDK inhibitor, fulvestrant, everolimus, or anyagent whose mechanism of action is to inhibit the PI3K-mTOR pathway

• Known active uncontrolled or symptomatic Central Nervous System (CNS) metastasescarcinomatous meningitis, or leptomeningeal disease

• Other active malignancy within 3 years prior to randomization, except for adequatelytreated basal cell or squamous cell skin cancer, or carcinoma in situ

• Major surgery or radiation within 4 weeks prior to study intervention

• Last anti-cancer treatment within 2 weeks prior to study intervention

• Participation in other studies involving investigational drug(s) within 4 weeksprior to study entry

• Pregnant or breastfeeding female participant

• Active inflammatory gastrointestinal (GI) disease, known diverticular disease orprevious gastric resection or lap band surgery including impairment ofgastrointestinal function or GI disease